Psychedelics
December 24, 2024
Fayzan Rab
At the intersection of medicine, psychedelics, and social impact stands Fayzan Rab, an MD Candidate at Emory University School of Medicine who brings a fascinating blend of experiences to his current role as a clinical researcher at the Emory Center for Psychedelics and Spirituality. His research explores crucial questions surrounding the emerging psychedelic therapy landscape, from...
Neuropharmacology
December 24, 2024
Chloé Galipeau, Zsolt Lenkei, Miguel Farinha‐ferreira et al.
17 citations
There is renewed interest in psychedelics, such as psilocybin, as therapies for multiple difficult-to-treat psychiatric disorders. Even though psychedelics can induce highly pleasant or aversive experiences, depending on multiple personal and environmental factors, there is little research into how such experiences impact post-acute mood-altering actions. Here we aimed at offsetting this gap....
Frontiers in Psychiatry
December 23, 2024
Kevin T Mintz, Brinn Gammer, Amanda J Khan et al.
correction
[This corrects the article DOI: 10.3389/fpsyt.2022.914458.].
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
December 22, 2024
Bhavya Bakshi, Sandeep Yerraguntla, Carmel Armon et al.
1 citation
ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no...
Medicina academica integrativa.
December 20, 2024
Tamara Trajbarič
Good mental health is foundational for individual and societal well-being, enabling resilience, personal growth, and active community engagement. Despite the availability of pharmacological and non-pharmacological treatments, many individuals experience partial or non-response, delayed therapeutic effects, and adverse side effects. Increasingly, individuals are exploring the use of psychedelics...
Psychotherapy in the Third Millennium - Cross-Cutting Themes and Proposals for Reflection
December 20, 2024
Eliana Mea, Paola Clemente
Can psychedelic-assisted psychotherapy (PAT) serve as a paradigm for describing and navigating a profound transformative experience of the self? This model of therapy has ignited an intense debate in recent years that seems aimed at calling into question, more than the various currents of psychotherapy, the model of psychiatric care that has lost over time the real capacity to address the...
Journal of Nature and Science of Medicine
December 17, 2024
N. Alyahya, Eithar A. Al Saleem
2 citations
In this review, studies focusing on the therapeutic use of psychedelics for treating mental health disorders published since 2010 have been examined. A systematic literature search was conducted using Medline and EBSCO. After extracting data from 19 papers, an analysis was performed. Critical evidence highlighting the effectiveness of psychedelic drugs in treating depression, anxiety,...
Psychedelics
December 17, 2024
Zachary Bosshardt, Jessica L Maples-Keller, Deanna M Kaplan et al.
Social attitudes, policy, and perceptions of psychedelics are currently undergoing considerable change. Growing public salience of psychedelics has been accompanied by the emergence of conferences focused on psychedelic education and dialogue. Attendees at such events compose an important group of stakeholders in psychedelic science and practice; their views of psychedelics can be valuable for...
bioRxiv (Cold Spring Harbor Laboratory)
December 17, 2024
J. Hudson Barnett, Kennedi T. Todd, Joseph Benetatos et al.
1 citation
preprint
Abstract Psilocybin is a psychedelic tryptamine that has emerged as a potential candidate for the treatment of a variety of conditions, including treatment resistant depression and post-traumatic stress disorder. Clinical trials which have assessed the efficacy of psilocybin for these conditions report a rapid and sustained improvement in patient- and clinician-rated depression scores. The...
Deutsches Ärzteblatt international
December 16, 2024
Moritz Spangemacher, Andrea Jungaberle, Henrik Jungaberle et al.
3 citations
Treatment with psilocybin differs fundamentally from classic psychopharmacotherapy. Its potentially transdiagnostic, rapid, and sustainable efficacy and its positive effect on further dimensions of mental health beyond the patient's symptoms and psychopathology imply that it may have diseasemodifying and salutogenic mechanisms of action. Psychotherapy accompanied by the administration of...